Development of dendritic-cell based prostate cancer vaccine

B A Tjoa1, G P Murphy

  • 1Pacific Northwest Cancer Foundation, 13758 Lake City Way NE, Suite 200, Seattle, WA 98125, USA. benhenry@uswest.net

Immunology Letters
|September 21, 2000
PubMed
Summary

Novel dendritic cell vaccines offer a promising new avenue for treating metastatic prostate cancer by activating the patient's immune system. These advanced immunotherapies aim to overcome limitations of current treatments.

Related Concept Videos